進行性腎細胞がん治療の世界市場レポート 2025年

進行性腎細胞がん治療市場規模は、今後数年で力強い成長が見込まれます。2029年にはCAGR7.7％で117億7,000万米ドルに成長します。予測期間における成長の原動力は、遺伝性疾患の罹患率の増加、慢性高血圧の有病率の上昇、チロシンキナーゼ阻害剤の採用、腎臓がんに対する意識の高まり、研究開発投資の増加などです。主な動向としては、診断の技術的進歩、標的治療の革新、経口治療法の開発、リキッドバイオプシー技術の進歩、薬剤開発における人工知能の統合などが挙げられます。

遺伝的疾患の有病率の増加は、進行腎細胞がん（RCC）治療市場の成長を促進すると予想されます。遺伝的疾患とは、DNAの異常に起因する障害や疾患のことで、両親から遺伝する場合もあれば、個人の生涯の間に発生する突然変異によって生じる場合もあります。遺伝性疾患の罹患率の増加は、診断技術の進歩、認知度の向上と報告、遺伝的素因と相互作用する環境やライフスタイルの要因に起因しています。進行腎細胞がん（RCC）治療は、特定の分子経路を標的とすることにより、腫瘍の発生と進行の遺伝的要因に対処する個別化治療を可能にし、遺伝的疾患の管理において重要な役割を果たしています。例えば、英国を拠点とする登録慈善団体ジーン・ピープルは、2023年6月、子どもの25人に1人が遺伝的疾患に罹患しており、英国では240万人以上が遺伝的疾患を抱えて生活していると推定しています。さらに、英国では毎年約3万人の新生児と子供が遺伝性疾患と診断されています。その結果、遺伝性疾患の有病率の増加が進行性腎細胞がん（RCC）治療市場の拡大に拍車をかけています。

進行腎細胞がん（RCC）治療市場の主要企業は、治療効果と患者の転帰を改善するために、低酸素誘導因子-2α（HIF-2a）阻害剤などの革新的な治療法の開発に注力しています。HIF-2a阻害剤は、低酸素レベルに対する身体の反応を制御するタンパク質であるHIF-2aの活性を阻害するように設計された薬剤クラス別です。例えば、2023年12月、米国のヘルスケア企業であるMerck &Co.Inc.は、経口HIF-2a阻害剤WELIREG（ベルズチファン）の米国食品医薬品局（FDA）承認を取得しました。この画期的な治療は、特にPD-1またはPD-L1阻害剤とVEGF-TKI治療による前治療歴のある患者を対象としています。今回の承認は、治療選択肢が限られている患者集団に新たな治療選択肢を導入するものであり、進行RCCの疾患管理と転帰を改善する可能性を提供するものであるため、意義深いものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界進行性腎細胞がん治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の進行性腎細胞がん治療市場：成長率分析
• 世界の進行性腎細胞がん治療市場の実績：規模と成長, 2019-2024
• 世界の進行性腎細胞がん治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界進行性腎細胞がん治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の進行性腎細胞がん治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生物学的製剤
• 放射線治療
• 化学療法
• ホルモン
• ワクチン療法
• その他の治療法
• 世界の進行性腎細胞がん治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 保護者
• オーラル
• その他の投与経路
• 世界の進行性腎細胞がん治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん調査機関
• 外来手術センター
• その他のエンドユーザー
• 世界の進行性腎細胞がん治療市場、生物製剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 免疫チェックポイント阻害剤
• サイトカイン療法
• 標的小分子阻害剤
• 世界の進行性腎細胞がん治療市場放射線治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線治療（EBRT）
• 定位放射線治療（SBRT）
• 陽子線治療
• 世界の進行性腎細胞がん治療市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラチナ製剤化学療法
• 代謝拮抗剤
• アルキル化剤
• 世界の進行性腎細胞がん治療市場ホルモン療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンドロゲン除去療法（ADT）
• エストロゲン受容体モジュレーター
• 世界の進行性腎細胞がん治療市場ワクチン療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペプチドベースのがんワクチン
• 樹状細胞ワクチン
• DNAベースのがんワクチン
• 世界の進行性腎細胞がん治療市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 凍結療法
• 高周波アブレーション（RFA）
• 併用療法

第7章 地域別・国別分析

• 世界の進行性腎細胞がん治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の進行性腎細胞がん治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 進行性腎細胞がん治療市場：競合情勢
• 進行性腎細胞がん治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Ipsen SA
• Exelixis Inc.
• BeiGene Ltd.
• Bavarian Nordic A/S
• Telix Pharmaceuticals Limited
• CRISPR Therapeutics AG
• Beijing Scitech-Mq Pharmaceuticals Limited
• HUTCHMED（China）Limited
• Arcus Biosciences Inc.
• NGM Biopharmaceuticals Inc.
• Mirati Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 進行性腎細胞がん治療市場2029：新たな機会を提供する国
• 進行性腎細胞がん治療市場2029：新たな機会を提供するセグメント
• 進行性腎細胞がん治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Advanced renal cell carcinoma (RCC) treatment encompasses medical interventions and therapies designed to manage and improve outcomes in later stages of the disease, where the cancer has spread beyond the kidney. These treatments typically include targeted therapies, immunotherapy, and, in some cases, radiation therapy to slow cancer progression and relieve symptoms.

The primary treatment options for advanced renal cell carcinoma (RCC) consist of biologics, radiation therapy, chemotherapy, hormone therapy, vaccine therapy, and other approaches. Biologics, which are derived from living organisms, specifically target cancer cells and boost the immune system, playing a crucial role in advanced RCC treatment. These medications can be administered via different routes, including parenteral, oral, and others. Various healthcare providers, such as hospitals, cancer research institutes, ambulatory surgical centers, and others, utilize these treatments.

The advanced renal cell carcinoma (RCC) treatment market research report is one of a series of new reports from The Business Research Company that provides advanced renal cell carcinoma (RCC) treatment market statistics, including the advanced renal cell carcinoma (RCC) treatment industry global market size, regional shares, competitors with the advanced renal cell carcinoma (RCC) treatment market share, detailed advanced renal cell carcinoma (RCC) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the advanced renal cell carcinoma (RCC) treatment industry. This advanced renal cell carcinoma (RCC) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The advanced renal cell carcinoma treatment market size has grown strongly in recent years. It will grow from $8.10 billion in 2024 to $8.75 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the rising geriatric population, an increasing prevalence of smoking, a surge in hypertension cases, higher healthcare expenditure, and a growing number of renal cancer cases.

The advanced renal cell carcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $11.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be driven by the increasing incidence of genetic conditions, the rising prevalence of chronic high blood pressure, the adoption of tyrosine kinase inhibitors, greater awareness of kidney cancer, and increased investments in research and development. Key trends include technological advancements in diagnostics, innovations in targeted therapies, the development of oral treatment options, progress in liquid biopsy technology, and the integration of artificial intelligence in drug development.

The increasing prevalence of genetic conditions is expected to drive the growth of the advanced renal cell carcinoma (RCC) treatment market. Genetic conditions are disorders or diseases resulting from DNA abnormalities, which may be inherited from parents or arise due to mutations occurring during an individual's lifetime. The rising incidence of genetic conditions is attributed to advancements in diagnostic technologies, improved awareness and reporting, as well as environmental and lifestyle factors that interact with genetic predispositions. Advanced renal cell carcinoma (RCC) treatment plays a crucial role in managing genetic conditions by targeting specific molecular pathways, enabling personalized therapies that address the genetic drivers of tumor development and progression. For example, in June 2023, Gene People, a UK-based registered charity, estimated that 1 in 25 children is affected by genetic conditions, with more than 2.4 million individuals in the UK living with a genetic disorder. Additionally, approximately 30,000 newborns and children are diagnosed with genetic conditions annually in the UK. As a result, the increasing prevalence of genetic conditions is fueling the expansion of the advanced renal cell carcinoma (RCC) treatment market.

Leading companies in the advanced renal cell carcinoma (RCC) treatment market are focusing on the development of innovative therapies, such as hypoxia-inducible factor-2 alpha (HIF-2a) inhibitors, to improve treatment effectiveness and patient outcomes. HIF-2a inhibitors are a class of drugs designed to block the activity of HIF-2a, a protein that regulates the body's response to low oxygen levels. For instance, in December 2023, Merck & Co. Inc., a US-based healthcare company, received U.S. Food and Drug Administration (FDA) approval for WELIREG (belzutifan), an oral HIF-2a inhibitor. This groundbreaking treatment is specifically intended for patients previously treated with PD-1 or PD-L1 inhibitors and VEGF-TKI therapies. The approval is significant as it introduces a novel therapeutic option for a patient population with limited treatment alternatives, offering potential for improved disease management and outcomes in advanced RCC.

In December 2023, Exelixis Inc., a US-based biotechnology company, entered into a partnership with Arcus Biosciences Inc. to accelerate the development of novel cancer therapies. Through this collaboration, Exelixis and Arcus Biosciences aim to advance treatments for advanced renal cell carcinoma and other solid tumors, leveraging the STELLAR-009 clinical trial to drive innovation. Arcus Biosciences Inc. is a US-based biotechnology company specializing in renal cell carcinoma treatment solutions.

Major players in the advanced renal cell carcinoma treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen SA, Exelixis Inc., BeiGene Ltd., Bavarian Nordic A/S, Telix Pharmaceuticals Limited, CRISPR Therapeutics AG, Beijing Scitech-Mq Pharmaceuticals Limited, HUTCHMED (China) Limited, Arcus Biosciences Inc., NGM Biopharmaceuticals Inc., Mirati Therapeutics Inc.

North America was the largest region in the advanced renal cell carcinoma treatment market in 2024. The regions covered in advanced renal cell carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the advanced renal cell carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The advanced renal cell carcinoma (RCC) treatment market includes revenues earned by entities by providing services such as targeted therapy administration, nephrectomy, medical consultation services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Advanced Renal Cell Carcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on advanced renal cell carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for advanced renal cell carcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The advanced renal cell carcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Biologics; Radiation Therapy; Chemotherapy; Hormone; Vaccine Therapy; Other Treatments
• 2) By Route Of Administration: Parental; Oral; Other Route Of Administrations
• 3) By End User: Hospitals; Cancer Research Institutes; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Biologics: Monoclonal Antibodies; Immune Checkpoint Inhibitors; Cytokine Therapy; Targeted Small Molecule Inhibitors
• 2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Stereotactic Body Radiation Therapy (SBRT); Proton Beam Therapy
• 3) By Chemotherapy: Platinum-Based Chemotherapy; Antimetabolites; Alkylating Agents
• 4) By Hormone Therapy: Androgen Deprivation Therapy (ADT); Estrogen Receptor Modulators
• 5) By Vaccine Therapy: Peptide-Based Cancer Vaccines; Dendritic Cell Vaccines; DNA-Based Cancer Vaccines
• 6) By Other Treatments: Cryoablation; Radiofrequency Ablation (RFA); Combination Therapy
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Advanced Renal Cell Carcinoma Treatment Market Characteristics

3. Advanced Renal Cell Carcinoma Treatment Market Trends And Strategies

4. Advanced Renal Cell Carcinoma Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Advanced Renal Cell Carcinoma Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Advanced Renal Cell Carcinoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Advanced Renal Cell Carcinoma Treatment Market Growth Rate Analysis
• 5.4. Global Advanced Renal Cell Carcinoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Advanced Renal Cell Carcinoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Advanced Renal Cell Carcinoma Treatment Total Addressable Market (TAM)

6. Advanced Renal Cell Carcinoma Treatment Market Segmentation

• 6.1. Global Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• Radiation Therapy
• Chemotherapy
• Hormone
• Vacccine Therapy
• Other Treatments
• 6.2. Global Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parental
• Oral
• Other Route Of Administrations
• 6.3. Global Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Research Institutes
• Ambulatory Surgical Centers
• Other End Users
• 6.4. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Immune Checkpoint Inhibitors
• Cytokine Therapy
• Targeted Small Molecule Inhibitors
• 6.5. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy (EBRT)
• Stereotactic Body Radiation Therapy (SBRT)
• Proton Beam Therapy
• 6.6. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Platinum-Based Chemotherapy
• Antimetabolites
• Alkylating Agents
• 6.7. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Androgen Deprivation Therapy (ADT)
• Estrogen Receptor Modulators
• 6.8. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Vaccine Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peptide-Based Cancer Vaccines
• Dendritic Cell Vaccines
• DNA-Based Cancer Vaccines
• 6.9. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cryoablation
• Radiofrequency Ablation (RFA)
• Combination Therapy

7. Advanced Renal Cell Carcinoma Treatment Market Regional And Country Analysis

• 7.1. Global Advanced Renal Cell Carcinoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Advanced Renal Cell Carcinoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Advanced Renal Cell Carcinoma Treatment Market

• 8.1. Asia-Pacific Advanced Renal Cell Carcinoma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Advanced Renal Cell Carcinoma Treatment Market

• 9.1. China Advanced Renal Cell Carcinoma Treatment Market Overview
• 9.2. China Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Advanced Renal Cell Carcinoma Treatment Market

• 10.1. India Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Advanced Renal Cell Carcinoma Treatment Market

• 11.1. Japan Advanced Renal Cell Carcinoma Treatment Market Overview
• 11.2. Japan Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Advanced Renal Cell Carcinoma Treatment Market

• 12.1. Australia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Advanced Renal Cell Carcinoma Treatment Market

• 13.1. Indonesia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Advanced Renal Cell Carcinoma Treatment Market

• 14.1. South Korea Advanced Renal Cell Carcinoma Treatment Market Overview
• 14.2. South Korea Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Advanced Renal Cell Carcinoma Treatment Market

• 15.1. Western Europe Advanced Renal Cell Carcinoma Treatment Market Overview
• 15.2. Western Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Advanced Renal Cell Carcinoma Treatment Market

• 16.1. UK Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Advanced Renal Cell Carcinoma Treatment Market

• 17.1. Germany Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Advanced Renal Cell Carcinoma Treatment Market

• 18.1. France Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Advanced Renal Cell Carcinoma Treatment Market

• 19.1. Italy Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Advanced Renal Cell Carcinoma Treatment Market

• 20.1. Spain Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Advanced Renal Cell Carcinoma Treatment Market

• 21.1. Eastern Europe Advanced Renal Cell Carcinoma Treatment Market Overview
• 21.2. Eastern Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Advanced Renal Cell Carcinoma Treatment Market

• 22.1. Russia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Advanced Renal Cell Carcinoma Treatment Market

• 23.1. North America Advanced Renal Cell Carcinoma Treatment Market Overview
• 23.2. North America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Advanced Renal Cell Carcinoma Treatment Market

• 24.1. USA Advanced Renal Cell Carcinoma Treatment Market Overview
• 24.2. USA Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Advanced Renal Cell Carcinoma Treatment Market

• 25.1. Canada Advanced Renal Cell Carcinoma Treatment Market Overview
• 25.2. Canada Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Advanced Renal Cell Carcinoma Treatment Market

• 26.1. South America Advanced Renal Cell Carcinoma Treatment Market Overview
• 26.2. South America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Advanced Renal Cell Carcinoma Treatment Market

• 27.1. Brazil Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Advanced Renal Cell Carcinoma Treatment Market

• 28.1. Middle East Advanced Renal Cell Carcinoma Treatment Market Overview
• 28.2. Middle East Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Advanced Renal Cell Carcinoma Treatment Market

• 29.1. Africa Advanced Renal Cell Carcinoma Treatment Market Overview
• 29.2. Africa Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Advanced Renal Cell Carcinoma Treatment Market Competitive Landscape And Company Profiles

• 30.1. Advanced Renal Cell Carcinoma Treatment Market Competitive Landscape
• 30.2. Advanced Renal Cell Carcinoma Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Advanced Renal Cell Carcinoma Treatment Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Regeneron Pharmaceuticals Inc.
• 31.4. Astellas Pharma Inc.
• 31.5. Ipsen SA
• 31.6. Exelixis Inc.
• 31.7. BeiGene Ltd.
• 31.8. Bavarian Nordic A/S
• 31.9. Telix Pharmaceuticals Limited
• 31.10. CRISPR Therapeutics AG
• 31.11. Beijing Scitech-Mq Pharmaceuticals Limited
• 31.12. HUTCHMED (China) Limited
• 31.13. Arcus Biosciences Inc.
• 31.14. NGM Biopharmaceuticals Inc.
• 31.15. Mirati Therapeutics Inc.

32. Global Advanced Renal Cell Carcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Advanced Renal Cell Carcinoma Treatment Market

34. Recent Developments In The Advanced Renal Cell Carcinoma Treatment Market

35. Advanced Renal Cell Carcinoma Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Advanced Renal Cell Carcinoma Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Advanced Renal Cell Carcinoma Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Advanced Renal Cell Carcinoma Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer